Biocon Biologics, a leading global biopharmaceutical company, has announced the extension of its insulin supply contract with the Ministry of Health in Malaysia. The contract, which was initially signed in 2019, has been extended for another three years, demonstrating the company’s commitment to providing affordable and high-quality insulin to the Malaysian market.
Under the contract, Biocon Biologics will continue to supply its recombinant human insulin (rh-insulin) products, including Insugen and Basalog, to the Malaysian government. These products will be used to support the country’s national healthcare system, providing essential treatment for patients with diabetes. The extended contract is expected to benefit over 300,000 patients in Malaysia who rely on insulin therapy.
Biocon Biologics’ insulin products have been widely accepted in Malaysia due to their high quality, efficacy, and affordability. The company’s rh-insulin products are manufactured at its state-of-the-art facility in Bangalore, India, which has been inspected and approved by regulatory agencies in several countries, including the US FDA and the EU’s EMA.
The extension of the contract is a significant milestone for Biocon Biologics, as it reinforces the company’s position as a trusted partner for governments and healthcare systems worldwide. The company’s commitment to providing affordable and accessible healthcare solutions has made a significant impact in Malaysia, where diabetes is a growing health concern.
According to the International Diabetes Federation, Malaysia has one of the highest prevalence rates of diabetes in Asia, with over 3.5 million people living with the condition. The extended contract will enable Biocon Biologics to continue playing a vital role in supporting the Malaysian government’s efforts to combat diabetes and improve healthcare outcomes for patients.
Biocon Biologics’ CEO, Christiane Hamacher, commented, “We are proud to extend our partnership with the Malaysian Ministry of Health, demonstrating our commitment to providing high-quality, affordable insulin to patients in need. Our insulin products have made a significant impact in Malaysia, and we look forward to continuing our collaboration to improve healthcare outcomes for patients with diabetes.” The contract extension is a testament to Biocon Biologics’ dedication to making a positive impact on global healthcare, and the company is well-positioned to continue its mission of providing innovative and affordable healthcare solutions to patients worldwide.